Identification of the Anti-sickling Activity of Anogeissus leiocarpus and In Silico Investigation of Some of Its Phytochemicals

Taiwo O. Elufioye*, Babatunde M. Williams¹, Mojisola C. Cyril-Olutayo²

¹Department of Pharmacognosy, Faculty of Pharmacy, University of Ibadan, Ibadan, Nigeria.
²Drug Research and Production Unit, Faculty of Pharmacy, Obafemi Awolowo University, Ile Ife, Nigeria.

**Abstract**

**Background:** The anti-sickling activity of Anogeissus leiocarpus, a plant used for managing sickle cell disease (SCD), has been previously proven.

**Objectives:** This study investigated the anti-sickling mechanism of A. leiocarpus by probing its effects on Gardos channel (KCNN4), erythropoietin (EPO), erythropoietin receptor (EPOR), catalase (CAT), G6pD, D-type cyclins and cyclin-dependent kinase inhibitors (p21) expression as well as assessing in silico drug-likeness of reported compounds as EPOR agonist.

**Methods:** A total of 18 rats (45-76 g) were selected and divided into 6 groups (n=3). The control group was given water ad libitum, standard group was given 0.1 mL/kg of Ciklavit® and experimental group was given daily oral doses of 50-100 mg/kg body weight of crude methanol extract or ethyl acetate fraction (EA-PF). Haematological parameters were analyzed while histopathological and molecular studies of kidney and bone marrow were carried out, followed by RT-PCR analysis of KCNN4, EPO, EPOR, CAT, G6pD, p21, and cyclin-dependent kinase inhibitors. Docking studies of the reported compounds were also done.

**Results:** EA-PF had an insignificant (p>0.05) effect on haematological parameters compared to the basal group. While CAT and p21 acted in a positive feedback loop, G6pD was downregulated in the experimental groups. KCNN4 acted in a negative-feedback mechanism and the upregulation of EPOR and EPO was followed by increased reticulocytes. Kaempferol, quercetin, and catechin showed non-violation of Lipinski’s rule and high binding affinities of 6.5 kcal/mol, 6.7 kcal/mol, and 6.7 kcal/mol, respectively, for EPOR pocket compared to the co-crystallized ligand.

**Conclusion:** Results suggest that ethyl acetate fraction of Anogeissus leiocarpus achieved a steady state level of the Gardos channel and stimulation of EPO expression via EPOR agonist.

**Keywords:** Sickle cell anaemia, Anogeissus leiocarpus, Gardos channel, Erythropoiesis, Mechanism of action

---

**Background**

Sickle cell anaemia has emerged as a public health problem with a continued increase in low and middle-income countries especially in sub-Saharan Africa, with Nigeria having the highest number of sickle cell anaemia sufferers in the world (1, 2). The disease is characterized by chronic intravascular haemolysis due to abnormal red blood cells (RBCs) shape that leads to vaso-occlusive crises which is the hallmark of sickle cell disease (SCD) that creates economic burden and makes management difficult in developing countries (3, 4). However, the multifaceted pathophysiology of SCD makes it possible to interrupt the disease at different stages through disruption of the pathology-initiating step of hemoglobin S (HbS) polymerization by inducing higher concentrations of fetal hemoglobin, countering endothelial inflammatory and oxidative abnormalities, and improving erythrocyte rehydration (5). Therefore, a multi-target therapeutic approach appears to be most promising.

The biochemical interplay between SS (HbS/HbS) cell dehydration in vivo and Gardos channel (a Ca²⁺-sensitive, intermediate-conductance, K⁺-selective channel encoded KCNN4, IK1 or hSK4) has continued to receive considerable research attention. At physiological intracellular Ca²⁺ concentration, Gardos channels are inactive, but it is activated in low-K⁺ media and transient increase in Ca²⁺ levels in pathological as well as experimental states was observed. The resulting net loss of KCl and KHCO₃ is linked to osmotic-driven water loss that causes cell dehydration referred to as Gardos effect (6-
Blockade of the Gardos channel could then have a beneficial effect on the pathophysiology of SCD as a drug target (11-13). Drugs such as charybdotoxin, Clostrimazole (14), and Senicapoc (15) have been used as Gardos channel blockers. However, because of the drawbacks of these drugs, which include imperfect selectivity, poor efficacy and attendant toxicity (16), coupled with the fact that more effective therapeutics are required for managing SCD (17,18), the search for new drugs is desirable.

A large number of the world’s population resort to plants and traditional medicine for primary health care and the use of plant parts as drug and repositories of pharmacological compounds for drug candidate dates back to prehistoric times (19, 20). Several plants are being used in traditional medicine for the management of sickle cell anaemia and the anti-sickling activity of some of these plants has been scientifically verified. Cajanus cajan seeds (21), Zanthoxylum macrophylla roots (22, 23), Parqueutia nigrescens root (24), and Carica papaya leaf (25) have been proven to have anti-sickling activity. Some herbal formulations such as Niprisan (17) and Ajaworon (18) are also commercially available for managing the disease.

Anogeissus leiocarpus is a medicinal plant found in Nigeria’s flora with several reported biological activities. Its medicinal values include wound healing (26) as well as treatment for skin diseases, psoriasis, leprosy, diarrhea, fever, rheumatism, and cough (27, 28). The plant has been reported to possess antiproliferative properties against HepG2 hepatocarcinoma cells (29), antitumor activity via angiogenesis pathway (30), as well as antioxidant and antimicrobial activities (30-32). Phytochemical screening identified the presence of flavonoids, terpenoids, tannins, alkaloids, cardiac glycosides, saponins, steroids, anthraquinones, and phenolic compounds in the plant (26, 33).

The in vitro anti-sickling activity of recipe containing A. leiocarpus has been previously reported (34). In an earlier study, we also reported the inhibitory and reversal effects of extracts and fractions of the plant on sodium metabisulphite–induced polymerization of sickle cell haemoglobin (35). This study was, therefore, undertaken to elucidate the mechanism of anti-sickling activity of A. leiocarpus leaves by investigating its modulation on the basal expression levels of Gardos channel (KCNN4), erythropoietin (EPO), erythropoietin receptor (EPOR), catalase (CAT), glucose-6-phosphate dehydrogenase (G6PD), cyclin-dependent kinase inhibitor 1 (p21) and D-type cyclin (cyclin-D2) in rat model. Molecular docking study was also carried out to estimate the binding affinity of phytochemicals in the plant for EPOR, as a first step in exploring their pro-erythropoietic and hence anti-sickling potencies.

Materials and Methods

Plant Materials

Fresh plant leaves of Anogeissus leiocarpus were collected from the Botanical Garden, University of Ibadan, Nigeria. The plant was identified and authenticated by Mr. Oba at the Forest Herbarium Ibadan with the voucher number FHI 109890. The leaves were air-dried, pulverized and extracted with 100% methanol. The extract was filtered and the filtrate was concentrated in vacuo using the rotary evaporator. The methanol extract was fractionated into n-hexane, ethyl acetate, and water.

Drug Ciklavit® was purchased from Mosh Pharmacy, Bodija. Ibadan, Nigeria.

Animals

A total of 18 female albino rats (Swiss strain) weighing between 45-76 g were obtained from the Animal Unit (Centre for Biocomputing and Drug Development, Adekunle Ajasin University, Akungba-Akoko, Ondo State) and divided into six groups (n = 3). The rats were kept under standard laboratory conditions (room temperature range: 22°C-30°C; photoperiod: 12 h light and 12 h dark) all through the period of study and were fed with commercial pelleted broiler finisher feed (produced by Vital Feeds, Ondo, Nigeria) and tap water ad libitum. The experimental procedure was conducted according to the International, National and Institutional Guidelines for the Use and Care of Experimental Animals.

Experimental Design

The design of the experiment consisted of negative control group (group 0), which received feed and water ad libitum, positive control (group I,) which received 0.1 mL Ciklavit®, the test groups which included group II (50 mg/kg EA-PF), group III (100 mg/kg EA-PF), group IV (50 mg/kg crude extract), and group V (100 mg/kg crude extract). Different doses were administered orally using oropharyngeal cannula once daily for 28 days.

Haematology

At the end of the study, the rats were fasted overnight and anaesthetized with chloroform. Then, blood samples were collected into an EDTA-treated bottle by cardiac puncture for haematological analysis. Haematological analysis was done using Automated Hematologic Analyser (Coulter STKS, Beckman). Packed cell volume (PCV), white blood cell (WBC) count, haemoglobin concentration (HbC), RBC count, mean corpuscular volume (MCV), mean corpuscular haemoglobin (MCH), mean corpuscular haemoglobin concentration (MCHC), neutrophil, lymphocytes, basophil, eosinophil, monocyte, and platelet count were determined.

Histopathology

The kidneys and bone marrows were fixed in 10% formal-
saline, trimmed and embedded in paraffin wax. A manual microtome (Hedee, model no. KD-202C) was used to cut them into thin sections. The sections were subjected to deparaffinization, rehydration and staining with hematoxylin and eosin (H&E) dyes and mounted for regular histological investigation. The preparations obtained were visualized using a light microscope (Olympus microscope, binocular with camera attached model) at a magnification of ×200.

RNA Isolation
RNA was extracted by the method used by Stead et al (36). The kidney and bone marrow samples were put into separate Eppendorf tubes containing 100 μL RNA snap” ATL reagent (18 mM EDTA, 0.025% sodium dodecyl sulphate, 95% formamide, and 1% 2-mercaptop-ethanol) and stored at -70°C until RNA was extracted from them. The tissues were heated on a water-bath for 7 minutes at 95°C and mechanically homogenized. The lysate was centrifuged (LR 56495 Centrifuge Machine ABBOTT) at 16000 rpm for 30 minutes. The supernatant (containing RNA) was aspirated, treated with 5 μL of 3M sodium acetate (pH 5.2) and 800 μL cold EtOH, and stored for 1 hour at -7°C. Then, it was centrifuged at 16000 rpm for 30 minutes to form RNA pellets at the bottom and then the supernatant was decanted. RNA pellets were washed twice with 800 μL EtOH (70%) and cooled before re-dissolving in 50 μL nuclease-free water. The concentration was determined by measuring the absorbance at 260 nm (JENWAY 6305 Spectrophotometer) and all samples were diluted to the same concentration.

cDNA Synthesis
Two microliters RTase was added to 20 μL of total RNA and incubated in a thermocycler at 42°C for 1 hour and then at 65°C for 3 minutes for enzyme deactivation. The cDNA was then used as template for PCR amplification.

Reverse Transcription-Polymerase Chain Reaction
Reverse transcription-polymerase chain reaction (RT-PCR) was used to measure relative differences in mRNA levels and normalized against β-actin. Thirty-cycle PCR (MultiGene OptiMax, Labnet International, Inc. Thermocycler) was performed on cDNA template (5 μL) using Taq polymerase Master Mix (10X) (primers specific to different domains with their coding sequence), dNTPs, MgCl₂ buffer, reverse and forward primers, and nuclease-free water (5 μL). The specific primers used for rat/mouse β-actin cDNA were as follows: β-actin F5’-ACACTTTTCTACATGAGGCTGC-3’, β-actin R5’-ACCAGAGGCTACAGGACAAC-3’; F5’-CCGACACGGGCAAATAAA-3’; R5’-GAGGCCATAATCCGGATCTTC-3’ spanning the CAT domain; G6pD F5’-GCTATGCCCGTTCCATGCT-3’ and R5’- GCCTGCCCTACATCTGCGCC-3; GPX-1 F5’-AGTTCGGACATCAGGAGAATGGCA-3’ and R5’-TCACCATTACCTCGCAGTTCTCA-3’; EPOR - Cal-channel; Cyclin-D2; p21, and EPO. Each cycle consisted of denaturation at 94°C for 30 seconds, annealing at 55°C for 30 seconds, and extension at 72°C for 30 seconds. A 5-minute pre-denaturation step at 94°C and 5-minute pre-extension step at 72°C were carried out before and after the 30 cycles. The product was loaded into each well of a 0.5% agarose gel for electrophoresis.

Gel Electrophoresis
Amplicons were electrophoresed in 0.5% agarose gel using 0.5x TBE buffer (2.6 g Tris base, 5 g Tris boric acid, and 2 mL 0.5M EDTA), adjusted to pH 8.3 with Sodium hydroxide pellet, stained with 0.5 μL ethidium bromide and visualized as bands by transilluminator. ImageJ was used to crop and analyze the gel images.

Computational Prediction of Ligand Interaction
The X-ray crystal structure of the human EPOR complexed with an antibody (ABT007) was retrieved from the RCSB database and prepared for the docking prediction (37). ABT007 is a highly potent and specific agonistic antibody that interacts with EPOR at an accessible active site made up of Leu26, Trp64, Pro, Glu, 97, 107, His110, Arg111 Val112, and His114. Using ChemBioOffice suite of programs, three-dimensional models were generated for the seven flavonoids, folic acid and the amino acid phenylalanine (L-configuration) (Figure 1). Each compound was energy minimized using the steepest descent algorithm and once minimized, each ligand was saved in the protein databank format. The bound antibody, crystallographic water as well as other crystallographic excipients were removed from the EPOR molecule, after which all missing hydrogen atoms were added using AutoDock tool (38). Using the same docking suite of programs, Gasteiger charges were added to the EPOR molecular structure as well as all nine ligands important in particular for the computation of the electrostatic component of the binding free energies (ΔG). We then constructed a virtual rectangular cuboid, the docking grid, with xyz dimensions sufficiently wide (17Å by 30 Å by 30 Å) to cover all EPOR surface residues defining the epitope employed in interacting with ABT007 as well as the available cavities. Then, AutoDock Vina (39) docking runs were performed for each ligand using a flexible treatment of all torsional degrees of freedom in the ligand molecules while the EPOR structure was kept rigid. For each ligand molecule, the top performing bound ligand conformation was saved and analyzed.

Lipinski’s Rule of Five for Drug Likeliness and In Silico ADME Prediction
Six compounds identified in the plant were further evaluated for their drug-like behavior through the analysis of pharmacokinetic parameters required for absorption,
distribution, metabolism and excretion (ADME) using QikProp (40).

Statistical Analysis
Data were expressed as mean ± standard error of mean (SEM). Comparisons were made by one-way (ANOVA) followed by Dunnett’s multiple comparisons test using GraphPad Prism version 5.0. \( P < 0.05 \) was considered statistically significant.

Results
The effect of EA-PF and crude extract (CE) was investigated on haematological parameters, and histology of bone marrow and kidney of female Swiss albino rats. These effects were compared with groups that received Ciklavit® (standard drug) and water as placebo (basal control). Moreover, the modulatory effect of the extract and fractions on the expression of genes implicated in SCD was assessed and in silico study of the selected compounds was carried out.

Haematology
The ethyl acetate fraction slightly increased Hb concentration, MCHC, PCV, RBC, and platelet number while the methanol extract at 100 mg/kg increased WBC and all the tested drugs increased MCV. However, these changes in haematological parameters were not significant \( (P > 0.05) \) when compared with groups that received Ciklavit® (standard) and water (Figure 2).

Histology of the Bone Marrow
The results of the histological analysis revealed that rats in the basal control group showed high cellularity, normal shapes and sizes (Figure 3A) when compared with cells which assumed different shapes (poikilocytosis) and sizes (anisocytosis) observed in 50 mg/kg b.wt. EA-PF group (Figure 3C). In 100 mg/kg EA-PF group, an abundant number of cells with normal shapes and sizes were observed (Figure 3D). A scanty cellular population with serrated edges was observed in 50 mg/kg CE extract group (Figure 3E) compared to 100 mg/kg CE group, in which cell clumping, small-sized cells and a few abnormally shaped cells were observed (Figure 3F) whereas normally shaped nucleated cells and erythrocytes at the background were seen in Ciklavit® group (Figure 3B).

Histology of the Kidney
Normal histology of rat kidney (glomeruli, tubules, interstitium, and blood vessels) was found in the control group (Figure 4A) hence, no observable lesion. The glomeruli were evenly distributed with and well-packed tufts and tubules were normal with interstitial congestion. At 50 mg/kg, EA-PF-treated group exhibited mild proliferation of mesangial cells in the glomeruli. Moreover, tubules were ectatic and interstitium containing a few cells was observed (Figure 4C). However, no observable lesion was found in kidney of 100 mg/kg EA-PF-treated group (Figure 4D). A dose of 100 mg/kg b.wt. of CE induced atrophy in few of the glomerular tufts and less cellular (Figure 4E). This was supported by tubular epithelial cells which were degenerate and necrotic with prominent casts.
Figure 2. Effect of Ethyl-acetate Partitioned-fraction (EA-PF), Crude Extract (CRUDE) and Ciklavit® (CK) on Haematological Parameters of Nommoxic Female Swiss Albino rats for 28 Consecutive Days. Data show means ± SEM, n=3. * = P<0.05; ** = P<0.001 relative to basal control (BC).

Figure 3. Photomicrographs of Rat Bone Marrows Post-administration of EA-PF, Crude Extract and Ciklavit®, Respectively (A) Bone Marrow of Rat in the Control Group Received Feed + Water Ad Libitum; (B) Bone Marrow of Rat in Ciklavit® Group Received 0.1 ml/g Ciklavit®; (C and D) Bone Marrows of Rat Received 50 and 100 mg/kg BW EA-PF; (E and F) Bone Marrows of Rat Received 50 and 100 mg/kg BW Crude Extract.
in lumen. There were also a few interstitial cell reactions (Figure 4F). Ciklavit® at the concentration of 0.1 mL/kg b.wt. resulted in a few atrophic glomeruli with accentuated Bowman’s space compared to the control group. The tubules were ectatic and the epithelium was attenuated (Figure 4B).

Quantification of mRNA of Specific Genes by RT-PCR and Ethidium Bromide-Stained Agarose Gel Electrophoresis

Agarose gel electrophoresis of reverse transcription-PCR products was used for the detection of specific gene expression profile in the bone marrow and kidney tissues with relative intensities. Lanes 3-6 were obtained from co-exposure to 50 and 100 mg/kg b.wt. of EA-PF and CE while lanes 1 and 2 were basal control and Ciklavit® group, respectively.

**KCNN4 expression was modulated in a negative feedback loop in bone marrow (BM) tissues from rat.**

K$_{a,3.1}$ channels are well characterized to promote Ca$^{2+}$ entry by maintaining a driving force and negative membrane potential. To investigate the potential role of KCNN4 (calcium channel) in regulating erythrocyte dehydration, the mRNA expression of KCNN4 in BM tissues was examined in rats by RT-PCR. It was observed that the 100 mg/kg dose of EA-PF significantly suppressed the expression of KCNN4 ($P<0.05$) when compared with the other doses. However, the basal control group also showed a significant suppression (Figure 5A).

EPO and EPOR expressions were upregulated in kidney and bone marrow tissues from rat.

To investigate the possible effect of *A. leiocarpus* on EPO and EPOR, mRNA expression of specific genes was quantified by RT-PCR using gel electrophoresis. The relative expression levels of EPO and EPOR transcripts were qualitatively measured and modulation was investigated. It was observed that the EA-PF and the CE produced an increase in cell proliferation of EPOR in a dose-dependent manner with the CE having better effect (Figure 5C). However, the EA-PF at 100 mg/kg significantly increased the expression of EPO (Figure 5B).

**CAT, p21, and Cyclin-D2 were transcriptionally upregulated in bone marrow tissues from rat.**

Enzyme activity and transcriptional level of CAT gene, the main enzyme of antioxidative defence, was upregulated and induced in a dose-dependent manner by all the test drugs. The extract and fractions had better effect than the standard drug (Figure 5D). Downregulation of the expression of cyclin-dependent kinase 1 inhibitor (p21) in bone marrow tissues was observed in response to the 100 mg/kg EA-PF (Figure 5G) while Figure 5H showed that cyclin D2 was also upregulated dose-dependently.

**Downregulation of G6pD expression stimulated antioxidant-switch and cytoprotective effect of G6PD/NADPH/glutathione (GPX-1).**

The expression level of Glucose-6-phosphate dehydrogenase (G6pD) was higher in response to 100 mg/kg b.wt. EA-

---

**Figure 4.** Photomicrographs of Rat Kidneys Post-administration of EA-PF, Crude Extract and Ciklavit®, Respectively (A) Kidney of Rat in the Control Group Received Feed + Water Ad Libitum. (B) Kidney of Rat in Ciklavit® Group Received 0.1 ml/kg Ciklavit®; (C and D) Kidney of Rat Received 50 and 100 mg/kg BW EA-PF; (E and F) Kidney of Rat Received 50 and 100 mg/kg BW Crude Extract. T: tubules, G: glomerulus, and IN: interstitium; Hematoxylin and eosin stain, x200.
Anti-sickling Activity of Anogeissus leiocarpus

The obtained interaction energy values are presented in Table 1. All seven flavonoids demonstrated moderately strong binding interaction with EPOR even though marginal binding superiority was recorded for quercetin and catechin. Moreover, all flavonoids were slightly better than folic acid ($\Delta G = -6.3 \text{ kcal/mol}$), this is more so for quercetin ($-6.7 \text{ kcal/mol}$), catechin ($-6.7 \text{ kcal/mol}$), rutin ($-6.6 \text{ kcal/mol}$), and vitexin ($-6.6 \text{ kcal/mol}$), whose computed binding free energy values were less than folic acid ($0.2 \text{ kcal}$). With L-phenylalanine demonstrating the worst interaction strength with the active site of EPOR, it is very likely that a combination of multiple ring structures and hydrogen-bonding interactions are important for binding at this site. Indeed, a single modification involving the removal of the 3-hydroxyl group in quercetin and kaempferol increased binding by 0.2 kcal. This may suggest the possibility of optimizing the structure of the studied compounds to identify more specific binders.

It is important to note that while multiple cavities were present within the EPOR antibody target surface covered by the employed docking grid, the same cavity was recognized as the best site for ligand interaction by all nine ligands (Figure 6). Binding to this cavity allowed interaction with three important active site residues, Leu26, Arg111, and His114, directly overlooking the binding cavity and in the crystal structure involved in interaction with chain A of the agonistic antibody ABT007 (37). The other active site residues were majorly located in flat areas of EPOR epitope. The binding of the ligands to these shallow regions would come with a high entropic cost related to both desolvation of the ligand molecules and maintenance of an energetically unfavorable bound pose. Within the cavity, however, the bound pose of the ligands was supported by a number of energetically favorable factors including specific electrostatic and hydrogen bonding interactions between Arg111 and His114 of EPOR on one hand and the hydrogen bond donor and acceptor groups of the flavonoids on the other hand (Figure 7). Orienting the hydroxyl groups at 3 position parallel to the plane of the flavonoids ring C (as seen in quercetin and kaempferol) or orthogonal to it (catechin) appears to be trivial for influencing the interaction strength. This perhaps explains why both quercetin and catechin were found to bind to EPOR with equivalent strength. The examination of the

**Table 1. The Binding Free Energy Values for Folic Acid, Phenylalanine, and the 7 Studied Flavonoids**

| Ligand                  | $\Delta G$ (kcal/mol) |
|-------------------------|-----------------------|
| Quercetin               | -6.7                  |
| Catechin                | -6.7                  |
| Rutin                   | -6.6                  |
| Vitexin                 | -6.6                  |
| Kaempferol              | -6.5                  |
| Isoquercetin            | -6.5                  |
| Procyanidin B2 (P-B2)   | -6.3                  |
| Folic acid              | -6.3                  |
| Phenylalanine           | -4.7                  |
| Dehydroquercetin        | -6.9                  |
| Dehydrokaempferol       | -6.9                  |
**Figure 6.** ABT007 (blue ribbon) Interacting with Human EPOR (Surface Representation)  
EPOR is colored according to crystallographic thermal fluctuation while EPOR epitope residues involved in binding the antibody ABT007 are shown as blue surface. All nine docked ligands are shown in yellow stick representation superimposed on one another and interacting via a binding cavity that allows hydrogen bond interaction with Arg111. The image was generated using the Visual Molecular Dynamics (85) and the crystallographic structure 2JIX.pdb (37).

**Figure 7.** Quercetin (A) and Catechin (B) (surface representation; cyan, red and white depict carbon, oxygen and hydrogen atoms, respectively) Nested Within EPOR Binding Cavity  
The epitope-bearing chain C of EPOR is shown in solid white representation while the epitope amino acid residues are shown as blue, red, and white for basic, acidic and hydrophobic amino acids, respectively. Other EPOR chains interacting with its chain C are represented with whitish surface mesh. Figure 7C and D show active site interaction of EPOR Leu26, Arg111, Val112 and His114 with quercetin and catechin in stick representation, respectively. The image was generated using the Visual Molecular Dynamics (85).
binding interactions as shown in Figure 6 revealed the placement of 3-OH group in flavonoids and the phenyl ring B in the vicinity of the hydrophobic amino acid Leu26 of EPOR. While phenyl ring B in flavonoids appeared optimal for maintaining binding, the 3-OH group seems to be a structural disadvantage. We modified the basic structure of quercetin and kaempferol by removing the 3-OH group and recomputed the binding interaction. In both cases, we recorded a 0.2 kcal/mol improvement in the strength of binding to EPOR. It should, however, be noted that while the approach employed in this work can qualitatively predict the thermodynamic feasibility of an interaction with the epitope region of EPOR that has been recognized as a determinant in agonistic activity of ABT007, a more thorough accounting of the protein dynamical forces (currently beyond the immediate scope of this work) would be necessary for examining the ability of the flavonoids to perturb the structure of EPOR in a fashion conforming to agonistic perturbation of EPOR structure. For this, it would be necessary to perform three groups of multiple independent conformational sampling preferably using enhanced sampling techniques such as the Hamiltonian replica exchange molecular dynamics and Markov state modelling as follows: (a) EPOR protein alone, (b) EPOR complexed with ABT007, and (c) EPOR complexed with the flavonoids. The similarity in the force distribution pattern and the conformational microstates of EPOR obtained with bound ABT007 and flavonoids would be predictive of agonistic tendencies of the latter.

The values are arranged in order of decreasing strength of interaction with the active site of EPOR. The removal of the 3-hydroxy group increased binding affinity of quercetin and kaempferol.

Lipinski’s Rule, ADME Descriptor and Toxicity Screening

Three flavonoids, quercetin, catechin, and kaempferol as well as folic acid were analyzed based on Lipinski’s rule of five and further subjected to ADME analysis using the Qikprop tool.

The predicted values according to Lipinski’s rule are as reported in Table 2 for both the hit compounds and folic acid. The hit compounds appeared to have performed better than folic acid on a number of specified parameters.

For intestinal absorption, quercetin and catechin showed relatively lower passive absorption (63% and 66%) compared to kaempferol (79% absorption) (Table 3). A Caco-2 cell permeability of 9.57744 shows a moderate permeability (4–70) for kaempferol.

The toxicity of the three most promising hit compounds was predicted using preADMET server. The Ames test was used to predict mutagenicity while mouse and rat models were used to predict carcinogenicity (Table 4).

Discussion

SCD is a general term that refers to both homozygous sickle cell anemia and heterozygous SCD. It is the most common genetic disorder caused by inheriting point mutations that change glutamic acid (Glu6) to valine (Val6) in the β chain of hemoglobin. On the basis of the current understanding of the molecular pathogenesis of SCD, a few independent treatment approaches have been proposed (41). These approaches include the use of agents that modify rheological properties of the blood, prevent dehydration of the hemoglobin, exhibit covalent binding to hemoglobin, increase the expression of gamma globin and fetal hemoglobin, increase the bioavailability of nitric

### Table 2. Lipinski’s Rule of 5 Parameters for Quercetin, Catechin and Kaempferol, and Folic Acid

| Ligand     | HBD | HBA | MW  | QPlogPo/w | Rot B° | TPSA | QLogBB | CNS | ROS |
|------------|-----|-----|-----|-----------|--------|------|--------|-----|-----|
| Kaempferol | 4   | 6   | 286.24 | 1.024 | 1      | 107  | -1.81  | -2  | 0   |
| Quercetin  | 5   | 7   | 302.24 | 0.349 | 1      | 127  | -2.332 | -2  | 0   |
| Catechin   | 5   | 6   | 290.272 | 0.422 | 1      | 110  | -1.941 | -2  | 0   |
| Folic acid | 6   | 10  | 441.404 | -2.81 | 9      | 209.8| -4.753 | -2  | 2   |

Molecular Descriptors of the Lead Hit Compounds: HBD: number of hydrogen-bond donors ≤ 5; HBA: number of hydrogen-bond acceptors ≤ 10; MW: molecular weight < 500; logPo/w: predicted octanol/water partition < 5; Polarity: number of rotatable bond (0-15), a topological parameter as a measure of molecular flexibility for oral drug bioavailability; Polarity: (A’2) topological polar surface area, a chemical descriptor for passive molecular transport through membranes

### Table 3. Absorption Properties of Quercetin, Catechin, and Kaempferol Using Qikprop Module (40)

| Ligand     | HIA (%) | QPLogPo/w | P_Caco | P_D0 | QPlogBB | #metab | QPlogERG | RO5 |
|------------|---------|-----------|--------|------|--------|--------|----------|-----|
| Kaempferol | 79.439289 | 0.286076 | 4.32558 | 3.021 | 4      | -5.03  |          | 0   |
| Quercetin  | 63.485215 | 0.172765 | 4.34341 | 2.782 | 5      | -4.943 |          | 1   |
| Catechin   | 66.707957 | 0.394913 | 4.29301 | 2.653 | 7      | -4.862 |          | 1   |

Molecular Descriptors of the Lead Hit Compounds: HIA: percentage of human intestinal absorption (<25% poor, > 80% high); logPo/w: predicted apparent Caco-2 cell permeability (P_Caco > 22 nm/s); Polarity: number of likely metabolic reactions (1-8); Polarity: predicted IC50 value for blockage of hERG K+ channels (acceptable range: above -5.0); Jorgensen’s rule of three (maximum is 3).
oxide and reduce iron overload (42). Others are stem cell transplantation, which is the only cure to date, and gene therapy (43).

In a previous study, we established the inhibitory and reversal effects of *A. leiocarpa* on sodium metabisulphite–induced polymerization of sickle cell haemoglobin (35). In a further attempt to explore the possible use of this plant in the management of SCD, this research was carried out to unfold the mechanism of its anti-sickling effect by analyzing the effects of extract and the most active fractions from the plant on hematological parameters, *KCNN4*, EPO (kidney), EPOR (bone marrow), *CAT*, G6pD, D-type cyclins (*cyclin D2*), and cyclin-dependent kinase inhibitors (*p21*) expression. In silico drug-likeness of some compounds already reported in the plant was also assessed as *EPOR* agonist.

The assessment of hematological parameters is one simple and convenient way of evaluating the effectiveness of a therapy in blood disorders such as SCD (44, 45). Hematological parameters such as MCH, red cell distribution width, and reticulocyte counts are important in the diagnosis, treatment and monitoring of SCD (44, 46). Leukocytes are readily accessible cell population and they are involved in SCD vasculopathy (47). The levels of MCH, WBC, basophil, eosinophils, neutrophils, lymphocytes, and monocytes were determined in response to Ciklavit and different extracts of *A. leiocarpa*. As observed, the methanol CE and ethyl acetate partitioned fraction of *A. leiocarpus* did not cause significant (*P* > 0.05) change in hematological parameters when compared to the basal control group (Figure 2). This finding corroborates the results obtained by Agaie et al and Chidozie et al (48, 49) whose studies revealed that significant hematological changes were not observed in extract treated groups when compared to the control. However, it was agreed that *A. leiocarpus* possess potent pro-hematopoietic agents capable of normalizing biochemical abnormalities associated with blood disorders (48, 49). Meanwhile, Sarkiyayi and Aileru (50) reported that methanol extract of the plant exhibited a dose-dependent increase in certain hematological parameters such as RBC count, platelet count, and MCH. Cells from the bone marrow were examined for the possible effect of the extract on the RBCs. There was an observable increase in the cellularity with normal shapes and sizes in the bone marrow of the animals treated with 100 mg/kg of both EA-PF and CE, which is comparable to the positive control (Figure 3A-F). Therefore, *A. leiocarpus* appeared to improve the number and quality of RBCs in the treated groups.

The *KCNN4*, also known as Gardos channel gene and found in human erythrocytes, is a gene encoding K$_{\text{c}}$3.1 protein which is a part of the voltage-independent potassium channel activated by intracellular calcium. This channel is considered important in SCD because it is the major pathway for cell shrinkage via KCl and water loss that occurs in SCD (51). In this study, we observed that the expression of *KCNN4* was suppressed in response to 100 mg/kg EA-PF (Figure 5A). This suggests that since K$^+$ efflux through the Gardos channel of human RBCs would be obstructed and Ca$^{2+}$ import through the calcium-release activated calcium channel reduced, leading to the prevention of Gardos channel activation in RBCs to prevent dehydration in SCD (Figure 5A). This indicates one possible mechanism of action of the extracts of *A. leiocarpus*.

EPO, also called hematopoietin or haemopoietin, is a hormone produced primarily by the kidneys and is responsible for controlling the production of RBC by regulating the differentiation and proliferation of erythroid progenitor cells in the bone marrow. Previous studies have reported low level of EPO in patients with SCD (52). However, patients with SCD who are not in crisis have high level of EPO but it is generally lower compared to healthy patients with chronic anaemia (53). EPO is also used in the management of SCD (54).

In this study, *A. leiocarpus* had a significant (*P* < 0.05) up-regulation effect on EPO with the best effect observed in the 100 mg/kg EA-PF (Figure 5B) as well as EPOR in bone marrow with CE at 100 mg/kg having the best effect (Figure 5C). One possible mechanism by which ethyl acetate fraction of *A. leiocarpus* may stimulate erythropoiesis is by decreasing the rate of oxidant-induced hemolysis due to the presence of antioxidants flavonoids in the plant (55). This antioxidant mechanism will usually prolong the average life span of individual RBCs. *A. leiocarpus* have been reported to contain high flavonoid content (31, 33, 56) and flavonoids in *A. leiocarpus* have been identified as responsible for the scavenging or chelating activity against oxidative stress (26, 57). Different researches have shown that the expression of EPO can be modulated by flavonoids. Esomunu et al (58) and Oluyemi et al (59) reported increased erythropoiesis in rat models received flavonoids extract of *Garcinia kola* while Zheng et al (60) reported that flavonoids of *Radix astragali* stimulated the expression of EPO in cultured human embryonic kidney fibroblasts.

Oxidative stress has been associated with the pathophysiology of several diseases including SCD. Oxidation reactions produce reactive oxygen species (ROS) which can start chain reactions capable of damaging cells of the body. Therefore, oxidative stress, which occurs in sickle

Table 4. The Results of Mutagenicity (Ames test) and Carcinogenicity (Mouse and Rat) of Ligands Calculated Using PreADMET Server

| Ligand    | Ames test (Mutagenicity) | Carcinogenicity | Mouse | Rat |
|-----------|--------------------------|----------------|-------|-----|
| Kaempferol | Mutagenic                | Negative       | Positive |     |
| Quercetin  | Mutagenic                | Negative       | Positive |     |
| Catechin  | Mutagenic                | Negative       | Negative |     |

10 Avicenna J Med Biochem, Volume 8, Issue 1, 2020
cell patients due to the constant release of ROS, can result
in endothelial dysfunction and acute inflammation (61).
Antioxidants, which include some vitamins (C and E) as
well as certain enzymes such as CAT, superoxide dismutase
(SOD), and peroxidases, are involved in terminating the
chain reaction generated by ROS, thus playing a protective
role (61, 62). From our studies, there was an upregulation
of CAT transcription in a dose-dependent manner in the
BM of animals received different doses of the extract and
fraction of A. leiocarpus (Figure 5D). Both the ethyl acetate
fraction and the methanol extract had a significant effect
compared to the basal and positive control groups. This
then suggests the possible protection of RBCs from the
deleterious effects of ROS in sickle cell anemia. This activity
can also be attributed to the presence of flavonoids in the
plant. Flavonoids are known to regulate the expression
of many genes (63). Specifically, the upregulation of the
expression of CAT has been attributed the certain
flavonoids like curcumin (64).

Various researchers have suggested different associations
between SCD and G6PD. They include no correlation
(65, 66), damaging (67,68), and beneficial (69, 70) effects.
Therefore, our study also evaluated the effect of the extracts
on G6PD gene expression. There was a significant increase
in the expression of the G6PD gene in the animals treated
with 100 mg/kg EA-PF when compared with other doses
(Figure 5F). However, this increase may have no implication
as previous research has reported no significant difference
in hematological parameters, incidence of painful episodes,
anemia episodes, sepsis or severity of hemolysis in patients
with or without G6PD deficiency (5, 14)

Cyclins are components of the core cell cycle machinery
involved in cell cycle progression. They form holoenzymes
and activate cyclin-dependent protein kinases (Cdks)
(71). Cyclin D is one of the most important cyclins and it
connects with four Cyclin-dependent kinases (Cdks 2, 4,
5, and 6) (72). Through activation of CDK4 and CDK6,
D-type cyclins accelerate G1/S to S-phase transition
and mediate mitogenic signals, including those signaled
through cytokine receptors (73). We observed a dose-
dependent increase in cyclin D2 expression in the treated
groups (Figure 5H). Enhanced cyclin D2 expression
could potentially promote proliferation of hematopoietic
stem and progenitor cells (74, 75). This could explain the
pro-hematological tendency of A. leiocarpus as
reported by previous studies (48, 49). However, cyclin-
dependent kinase inhibitors (CKIs) inhibit cell division
by antagonizing the activities of specific Cdks. CKIs
include p21 and p27 which are potent inhibitors of CDK2
that is responsible for the regulation of hematopoietic
proliferation (76). The ability of p21 to promote cell
cycle inhibition positively correlates with the suppression
of genes that are important for cell cycle progression
(77). Therefore, downregulation of the gene encoding
p21 would be of advantage in the management of SCD.

Our study showed a higher expression of p21 gene in the
treated groups when compared with both the positive and
basal control groups (Figure 5G). This indicates that the
plant probably does not work through this mechanism of
downregulating cyclin-dependent kinase inhibitors.

Protein-ligand molecular interaction plays a significant
role in structure-based drug design by predicting the
binding conformation or pose of the ligand bound
to the protein, and this can be quantified based on the
shape and electrostatic interaction between the ligand
and protein (78). The totality of interaction observed is
approximated to be the docking score of the ligand into
the binding pocket of the protein (78). Docking score is
expressed in negative value of energy in Kcal/mol where
the lower the negative total energy (E), the stronger the
interaction between the ligands and the protein (79).

Therefore, docking experiments predict the best binding
conformation of compounds at the binding pocket of the
protein and the interaction between the ligand and the
residues at the active site of the protein. In silico study was
carried out to predict pro-erythropoietic activity of the hit
compounds through molecular docking. The mechanism
of interaction of potential stimulation of the EPOR is
dependent on the formation of different types of bonds
between the amino acid residues at the active site and the
ligand. The library of compounds generated was subjected
to docking experiment to determine those with high
binding energy. The docking result showed good binding
energy against EPOR for three compounds (quercetin,
kaempferol, and catechin) of A. leiocarpus out of the six
compounds retrieved from NCBI database and screened.
The docking results and ADME screening of the phyto-
chemical and co-crystallized ligands are shown in Tables 1
and 4. Quercetin, kaempferol, and catechin produced better
scoring results than folic acid, thus implying a high
EPOR binding affinity. Codorniu-Hernández et al (80) carried
out docking studies to understand flavonoid–protein
interactions. The results indicated that hydrophilic amino
acid residues demonstrated high-affinity interactions with
flavonoids, as it was predicted by the theoretical affinity
order. The docking modes among catechin molecules
and four proteins (human serum albumin, transthyretin,
estase, and renin) also give credence to this finding (81).

Physically significant descriptors and pharmacologically
relevant properties of compounds among which were
molecular weight, log p, H-bond donors, and H-bond
acceptors according to the Lipinski’s rule of five (82), which
is a rule of thumb to evaluate drug-likeness or determine
if a chemical compound with a certain pharmacological
or biological activity has properties that would make it
a likely orally active drug in humans. The rule describes
molecular properties important for drug pharmacokinetics
in the human body, including its ADME. The in silico
protein target studies and ADME toxicity analysis revealed
that Kaempferol, quercetin, and catechin presented good
absorption parameters and potentials to permeate the blood brain barrier with less biological risk in mouse compared to rat (Table 4). Additionally, the predicted IC₅₀ values for quercetin and catechin were within an acceptable range. Kaempferol and quercetin were consistent with Jørgensen’s “rule of three”: log S > −6, PCaco > 30 nm/s, and maximum number of primary metabolites of 6 (Table 4) (83). It is known that glycosylation of flavonoids increases solubility in the aqueous cellular environment and protects the reactive hydroxyl groups from auto-oxidation (84), as the most reactive hydroxyl groups (7-OH in flavones or the 3-OH in flavonols) in flavonoids are generally glycosylated. This also explains why kaempferol and quercetin are more likely to be orally available with a high drug-likeness property.

Conclusion
Anogeissus leiocarpus leaves showed effects on both EPO and EPORs in female Swiss albino rats, with a potential to reverse pathologic dehydration of red cells under sickling conditions. The upregulation of EPO and negative feedback mechanism of the calcium channel in the experimental models proves its potency as both a pro-erythropoietic agent and a Gardos channel blocker. Extracts from the plant also enhanced cyclin D2 expression and thus could potentially promote the proliferation of hematopoietic stem cells. It also upregulated CAT gene expression suggesting that it can protect RBCs from the damaging effects of ROS experienced in sickle cell anemia. The strong ligand-receptor binding complex predicted from computational method was consistent with the upregulation of EPOR and EPO expression, thus contributing to erythropoiesis stimulation. Compounds in the plant also satisfied the Lipinski’s rule of five with zero violations suggesting that these phytochemicals portend to be orally active compounds that may be useful in managing SCD.

Authors’ Contributions
TOE designed the experiments, supervised the work, interpreted the data and produced the final manuscript. BMW carried out the experimental work, analyzed the data and wrote the draft manuscript. MCC Co-supervised the work and analyzed the data and edited the manuscript.

Conflict of Interest Disclosures
Authors declare no conflict of interests.

Ethical Issues
The experimental procedure was conducted according to the International, National and Institutional Guidelines for the Use and Care of Experimental Animals.

Acknowledgements
The authors would like to express their gratitude to Dr. I.O Omotuyi from the Centre for Biocomputing and Drug Development, Adekunle Ajayi University, Akungba-Akoko.

References
1. Piel FB, Hay SI, Gupta S, Weatherall DJ, Williams TN. Global burden of sickle cell anaemia in children under five, 2010-2050: modelling based on demographics, excess mortality, and interventions. PLoS Med. 2013;10(7):e1001484. doi: 10.1371/journal.pmed.1001484.
2. Ohinna C. Pain and Penalty of Sickle Cell Disease not Beyond Science. WHO, 2012.
3. Amer J, Ghoti H, Rachmilewitz E, Koren A, Levin C, Fibach E. Red blood cells, platelets and polymorphonuclear neutrophils of patients with sickle cell disease exhibit oxidative stress that can be ameliorated by antioxidants. Br J Haematol. 2006;132(1):108-13. doi: 10.1111/j.1365-2141.2005.05834.x.
4. Kauf TL, Coates TD, Huazhi L, Mody-Patel N, Hartzema AG. The cost of health care for children and adults with sickle cell disease. Am J Hematol. 2009;84(6):323-7. doi: 10.1002/ajh.21408.
5. Steinberg MH. Pathophysiologically based drug treatment of sickle cell disease. Trends Pharmacol Sci. 2006;27(4):204-10. doi: 10.1016/j.tips.2006.02.007.
6. Ataga KI, Reid M, Ballas SK, Yasin Z, Bigelow C, James LS, et al. Improvements in haemolysis and indicators of erythrocyte survival do not correlate with acute vaso-occlusive crises in patients with sickle cell disease: a phase III randomized, placebo-controlled, double-blind study of the Gardos channel blocker senicapoc (ICA-17043). Br J Haematol. 2011;153(1):92-104. doi: 10.1111/j.1365-2141.2010.08520.x.
7. Thompson-Vest N, Shimizu Y, Hunne B, Furness JB. The distribution of intermediate-conductance, calcium-activated, potassium (IK) channels in epithelial cells. J Anat. 2006;208(2):219-29. doi: 10.1111/j.1469-7580.2006.00515.x.
8. von Hahn T, Thiele I, Zingaro L, Hamm K, Garcia-Alzamora M, Kottgen M, et al. Characterisation of the rat SK4/K1 (K+) channel. Cell Physiol Biochem. 2001;11(4):219-30. doi: 10.1159/000051936.
9. Rhoda MD, Apovo M, Beuzard Y, Giraud F. Ca2+ permeability in deoxygenated sickle cells. Blood. 1990;75(12):2453-8.
10. Gardos G. The function of calcium in the potassium permeability of human erythrocytes. Biochim Biophys Acta. 1958;30(3):653-4. doi: 10.1016/0006-3002(58)90124-0.
11. Wulf H, Castle NA. Therapeutic potential of KCa3.1 blockers: recent advances and promising trends. Expert Rev Clin Pharmacol. 2010;3(3):385-96. doi: 10.1586/17512433.10.1111.
12. Faber ES, Sah P. Calcium-activated potassium channels: multiple contributions to neuronal function. Neuroscientist. 2003;9(3):181-94. doi: 10.1177/107385840309003011.
13. Brugnara C, Gee B, Armsby CC, Kurth S, Sakamoto M, Rifai N, et al. Therapy with oral clonotremazole induces inhibition of the Gardos channel and reduction of erythrocyte dehydration in patients with sickle cell disease. J Clin Invest. 1996;97(5):1227-34. doi: 10.1172/jci118537.
14. Steinberg MH, Brugnara C. Pathophysiologically-based approaches to treatment of sickle cell disease. Annu Rev Med. 2003;54:89-112. doi: 10.1146/annurev.med.54.100103.152439.
15. Stocker JW, De Franceschi L, McNaughton-Smith GA, Corrocher R, Beuzard Y, Brugnara C. ICA-17043, a novel Gardos channel blocker, prevents sickled red blood cell dehydration in vitro and in vivo in SAD mice. Blood. 2003;101(6):2412-8. doi: 10.1182/blood-2002-05.1433.
16. Gee BE. Biologic complexity in sickle cell disease: implications
for developing targeted therapeutics. ScientificWorldJournal. 2013;2013:694146. doi: 10.1155/2013/694146.

17. Iyamu EW, Turner EA, Asakura T. Niprisan (Nix-0699) improves the survival rates of transgenic sickle cell mice under acute severe hypoxic conditions. Br J Haematol. 2003;122(6):1001-8. doi: 10.1046/j.1365-2411.2003.03436.x.

18. Moody JO, Ojo OO, Omotade AO, Adeloyo AA, Olumese PE, Ogundipe AO. Anti-sickling potential of a Nigerian herbal formula (ajawaron HF) and the major plant component (Cissus populnea). CPK. Phytother Res. 2003;17(10):1173-6. doi: 10.1002/tr.1233.

19. World Health Organization (WHO). WHO Traditional Medicine Strategy: 2014-2023. Geneva: WHO; 2013.

20. Mbula JP, Kwembe JTK, Tshilanda DD, Ngobua KN, Kabena ON, Nsima SM, et al. Antisickling, antihemolytic and radical scavenging activities of essential oil from Entandrophragma cylindricum (Sprague) Sprague (Meliaceae). J Adv Med Life Sci. 2018;6(2):1-5. doi: 10.5281/zenodo.1167931.

21. Ekeki, Gh, Shode FO. Phenylalanine is the predominant antisickling agent in Cajanus cajan seed extract. Planta Med. 1990;56:41-3. doi: 10.1055/s-1990-963880.

22. Sofowora EA, Isaac-Sodoye WA, Ogunkoya LO. Isolation and characterisation of an antisickling agent from Fagara zanthoxyloides root. Lloydia. 1975;38(2):169-71.

23. Elekwa I, Monanu MO, Anosike EO. In vitro effects of aqueous extracts of Zanthoxylum macrophylla roots on adenosines triphosphates from human erythrocytes of different genotypes. Biokemistri. 2005;17(1):19-25. doi: 10.4314/biokem.v17i1.32584.

24. Kade II, Kotila OO, Ayelaye AO, Olawoye TL. Antisickling properties of Parqueutina nigrescens. Biomed Res. 2003;14:185-8.

25. Imaga NOA, Gbenle GO, Okachi VI, Akanhi SO, Edeogun SO, Ogbuehi V, et al. Antisickling property of Carica papaya leaf extract. Afr J Biomed Res. 2009;3(4):102-6.

26. Barku YY, Boye A, Ayaba S. Phytochemical screening and assessment of wound healing activity of the leaves of Anogeissus leiocarpus. Eur J Exp Biol. 2013;3(4):18-25.

27. Okpekton T, Yolou S, Gleye C, Roblot F, Loiseau P, Borisie C, et al. Antiparasitic activities of medicinal plants used in Ivory Coast. J Ethnopharmacol. 2004;90(1):91-7. doi: 10.1016/j.jep.2003.09.029.

28. Singh D, Baghel US, Gautam A, Baghel DS, Yadav D, Malik J, et al. The genus Anogeissus: a review on ethnopharmacology, phytochemistry and pharmacology. J Ethnopharmacol. 2016;194:30-56. doi: 10.1016/j.jep.2016.08.025.

29. Oughbami JO, Damaoiseaux R, France B, Onibiyo EM, Olugbami JO, Damoiseaux R, et al. A comparative assessment of antiproliferative properties of resveratrol and ethanol leaf extract of Anogeissus leiocarpus (DC) Guili and Perr against HepG2 hepatocarcinoma cells. BMC Complement Altern Med. 2017;17(1):381. doi: 10.1186/s12906-017-1873-2.

30. Hassan LEA, Al-Suedee FS, Fauld SM, Abdul Majid AMS. Evaluation of antioxidative, antiangiogenic and antitumor properties of Anogeissus leiocarpus against colon cancer. Angiotherapy. 2018;1(2):56-66.

31. Elufioye TO, Olaifa OA. Comparison of the antioxidiant activity with the total phenolic and total flavonoid contents of the leaves and stem-bark of Anogeissus leiocarpus (DC) Guili and Perr. (Combretaceae). Niger J Pharm Sci. 2016;12(2):71-81.

32. Konaté K, Kisedrèbègo M, Ouattara MB, Souza A, Lamin-Meda A, Nongozida Y, et al. Antibacterial potential of aqueous acetone extracts from five medicinal plants used traditionally to treat infectious diseases in Burkina Faso. Curr Res J Biol Sci. 2011;3(5):435-42.

33. Edewor TI, Akpor OB, Owa SO. Determination of antibacterial activity, total phenolic, flavonoid and saponin contents in leaves of Anogeissus leiocarpus (DC) Guili and Perr. J Coast Life Med. 2016;4(4):310-4. doi: 10.12980/jclm.4.2016.5-218.

34. Egunyomi A, Moody JO, Eletu OM. Antisickling activities of two ethnomedicinal plant recipes used for the management of sickle cell anaemia in Ibadan, Nigeria. Afr J Biotechnol. 2009;8(1):20-25.

35. Elufioye TO, Olaifa OA, Cyril-Olutayo MC. Inhibitory and reversal effects of extracts and fractions of Anogeissus leiocarpus (DC.) Guili & Perr. on sodium metabisulphite-induced polymerization of sickle cell haemoglobin Curr Tradit Med. 2019;5(3):257-67. doi: 10.2174/22130885666190412162414.

36. Stead MB, Agrawal A, Bowden KE, Nasrir R, Mohanty BK, Meegar RB, et al. RNAsnap: a rapid, quantitative and inexpensive method for isolating total RNA from bacteria. Nucleic Acids Res. 2012;40(20):e156. doi: 10.1093/nar/gks680.

37. Liu Z, Stoll VS, Devries PJ, Jakob CG, Xie N, Simmer RL, et al. A potent erythropoietin-mimicking human antibody interacts through a novel binding site. Blood. 2007;110(7):2408-13. doi: 10.1182/blood-2007-04-083998.

38. Morris GM, Hito R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, et al. AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J Comput Chem. 2009;30(16):2785-91. doi: 10.1002/jcc.21256.

39. Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem. 2010;31(2):455-61. doi: 10.1002/jcc.21334.

40. Schrödinger L. Release 2018-1: QiKProp, LLC. New York, NY: 2018.

41. Bunn HF. Pathogenesis and treatment of sickle cell disease. N Engl J Med. 1997;337(11):762-9. doi: 10.1056/nejm199709113371107.

42. de Melo TR, dos Reis Ercolin L, Chelucci RC, Melchior AC, Lanaro C, Chin CM, et al. Sickle Cell Disease—Current Treatment and New Therapeutical Approaches. In: Minshi A, ed. Inherited Hemoglobin Disorders. InTech Open; 2015. doi: 10.5772/60515.

43. Gardner RV. Sickle cell disease: advances in treatment. Ochsner J. 2018;18(4):377-89. doi: 10.31486/ij18.0076.

44. Yenilmez ED, Tuli A. Laboratory Approach to Anemia. In: Current Topics in Anemia. Intech Open; 2017. doi: 10.5772/70359.

45. Dong, M, Muzino T, Vinks AA. Opportunities for model-based precision dosing in the treatment of sickle cell anemia. Blood Cells Mol Dis. 2017;67:143-7. doi: 10.1016/j.bcmd.2017.08.007.

46. Hanna J, Wernig M, Markoulaki S, Sun CW, Meissner A, Cassidy JP, et al. Treatment of sickle cell anemia mouse model with iP3 cells generated from autologous skin. Science. 2007;318(5858):1920-3. doi: 10.1126/science.1152092.

47. Jison ML, Munson PJ, Barb JJ, Suffredini AF, Talwar S, Logun CM, et al. Blood mononuclear cell gene expression profiles characterize the oxidant, hemolytic, and inflammatory stress of sickle cell disease. Blood. 2004;104(1):270-80. doi: 10.1182/blood-2003-08-2760.

48. Agaie BM, Onyeyili PA, Muhammad BY, Ladan MJ. Some toxic effects of aqueous leaf extract of Anogeissus leiocarpus in rats. J Pharmacol Toxicol. 2007;2:4(4):396-401. doi: 10.3923/jpt.2007.396.401.

49. Chidozie VN, Adoga GI. Toxicological effects of aqueous extract of Anogeissus leiocarpus leaf, Carica papaya leaf, and Mangifera indica stem bark (a herbal product used against typhoid fever) on Allbino rats. Cancer Biol. 2014;4(4):26-34.

50. Sarkiayi S, Aileru AE. Phytochemical screening and hematological studies of the leaves of Anogeissus leiocarpus on gentamicin induced rats. Bagale J Pure Appl Sci. 2016;10(1):123-41.
Anogeissus leiocarpus

Elufioye et al

Steinberg MH, West MS, Gallagher D, Mentzer W. Effects of dehydrogenase deficiency and homozygous sickle cell disease. J Pediatr. 1969;74(4):544-51. doi: 10.1016/S0022-3476(69)80037-5.

Korotny-Ahulu Fl. Glucose-6-phosphate dehydrogenase deficiency and sickle-cell anemia. N Engl J Med. 1972;287(17):887-8. doi: 10.1056/nejm19721026287179.

Lewis RA, Kay RW, Hathorn M. Sickle cell disease and glucose-6-phosphate dehydrogenase. Acta Haematol. 1966;36(5):399-411. doi: 10.1111/j.1365-2141.1980.tb00920.x.

Piromelli S, Reindorf CA, Arzamian MT, Corash LM. Clinical and biochemical interactions of glucose-6-phosphate dehydrogenase deficiency and sickle-cell anemia. N Engl J Med. 1972;287(5):213-7. doi: 10.1056/nejm197208032870502.

Malumbres M, Barbaric M. Mammalian cyclin-dependent kinases. Trends Biochem Sci. 2005;30(11):630-41. doi: 10.1016/j.tibs.2005.09.005.

Malumbres M. Cyclin-dependent kinases. Genome Biol. 2014;15(6):122. doi: 10.1186/gb15-6.

Sasaki Y, Jensen CT, Karlsson S, Jacobsen SE. Enhanced expression of cyclin D2 promotes the proliferative potential of myeloid progenitors, accelerates in vivo myeloid reconstitution, and promotes rescue of mice from lethal myeloablation. Blood. 2004;104(4):986-92. doi: 10.1111/j.1528-0064.2003.tb15678.x.

Lam EW, Glassford J, Banerji L, Thomas NS, Scicsnki P, Klaus GG. Cyclin D3 compensates for loss of cyclin D2 in mouse B-lymphocytes activated via the antigen receptor and CD40. J Biol Chem. 2000;275(5):3479-84. doi: 10.1074/jbc.275.5.3479.

Palavson N, Wu WW, Parry D, Mahony D, Lam EW, Glassford J, et al. Cyclin D2 is essential for BCR-mediated proliferation and CD5 B cell development. Int Immunol. 2000;12(5):631-8. doi: 10.1093/intimm/12.5.631.

Sorrentino BP. Clinical strategies for expansion of haematopoietic stem cells. Nat Rev Immunol. 2004;4(11):878-88. doi: 10.1038/nri1487.

Karimian A, Abody M, Yousefi B. Multiple functions of p21 in cell cycle, apoptosis and transcriptional regulation after DNA damage. DNA Repair (Amst). 2016;42:63-71. doi: 10.1016/j.dnarep.2016.04.008.

Pagadala NS, Syed K, Tuzysyn J. Software for molecular docking: a review. Biophys Res. 2017;9(2):91-102. doi: 10.1021/acs.jbchem.7b00162.

Ashwini S, Varkony SP, Shantaram M. In Silico docking of polyphenolic compounds against Caspase 3-Hela cell line protein. Int J Drug Dev Res. 2017;9:28-32.

Codorniu-Hernández E, Roló-Naranjo A, Montero-Cabrera LA. Theoretical affinity order among flavonoids and amino acid residues: An approach to understand flavonoid–protein interactions. J Mol Struct. 2007;819(1-3):121-9. doi: 10.1016/j.theochem.2007.05.036.

Panche AN, Diwan AD, Chandra SR. Flavonoids: an overview. J Nutr Sci. 2016;5:e47. doi: 10.1017/jns.2016.41.

Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2001;46(1-3):1-26. doi: 10.1016/S0169-409x(00)00129-0.